EVOLUS, INC. (EOLS) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $649.39M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-529.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $643.21M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-278.00K.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $638.09M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-156.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $632.55M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-137.00K.
EVOLUS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | $649.39M | $-529.00K | $-679.77M | $-30.90M | 3 month · $5.64M | (m) | (m) |
| 2026-03-31 | $0.00 | $1.00K | $643.21M | $-278.00K | $-671.71M | $-28.78M | 3 month · $5.12M | (m) | (m) |
| 2025-12-31 | $0.00 | $1.00K | $638.09M | $-156.00K | $-661.04M | $-23.11M | 12 month · $20.80M | (m) | (m) |
| 2025-09-30 | $0.00 | $1.00K | $632.55M | $-137.00K | $-661.17M | $-28.76M | 3 month · $5.15M | (m) | (m) |
| 2025-06-30 | $0.00 | $1.00K | $627.38M | $-599.00K | $-645.43M | $-18.65M | 3 month · $4.52M | (m) | (m) |
| 2025-03-31 | $0.00 | $1.00K | $622.52M | $-839.00K | $-628.29M | $-6.60M | 3 month · $5.97M | (m) | (m) |
| 2024-12-31 | $0.00 | $1.00K | $615.83M | $-905.00K | $-609.40M | $5.52M | 12 month · $22.25M | (m) | (m) |
| 2024-09-30 | $0.00 | $1.00K | $609.19M | $-689.00K | $-602.61M | $5.89M | 3 month · $5.25M | (m) | (m) |
| 2024-06-30 | $0.00 | $1.00K | $603.35M | $-601.00K | $-583.44M | $19.31M | 3 month · $5.80M | (m) | (m) |
| 2024-03-31 | $0.00 | $1.00K | $591.09M | $-557.00K | $-572.09M | $18.44M | 3 month · $5.09M | (m) | (m) |
| 2023-12-31 | $0.00 | $1.00K | $538.72M | $-427.00K | $-558.98M | $-20.69M | 12 month · $16.46M | (m) | (m) |
| 2023-09-30 | $0.00 | $1.00K | $528.38M | $-606.00K | $-547.15M | $-19.37M | 3 month · $4.60M | (m) | (m) |
| 2023-06-30 | $0.00 | $1.00K | $523.73M | $-468.00K | $-530.23M | $-6.96M | 3 month · $4.17M | (m) | (m) |
| 2023-03-31 | $0.00 | $1.00K | $519.45M | $-416.00K | $-512.09M | $6.95M | 3 month · $3.29M | (m) | (m) |
| 2022-12-31 | $0.00 | $1.00K | $516.13M | $-337.00K | $-497.29M | $18.50M | 12 month · $10.83M | (m) | (m) |
| 2022-09-30 | $0.00 | $1.00K | $513.72M | $-368.00K | $-484.13M | $29.22M | 3 month · $2.48M | (m) | (m) |
| 2022-06-30 | $0.00 | $1.00K | $510.88M | $-165.00K | $-463.85M | $46.86M | 3 month · $2.98M | (m) | (m) |
| 2022-03-31 | $0.00 | $1.00K | $507.73M | $-103.00K | $-440.38M | $67.25M | 3 month · $2.96M | (m) | (m) |
| 2021-12-31 | $0.00 | $1.00K | $504.76M | $0.00 | $-422.88M | $81.88M | 12 month · $9.64M | (m) | (m) |
| 2021-09-30 | $0.00 | $1.00K | $502.11M | (m) | $-404.70M | $97.40M | 3 month · $2.50M | (m) | (m) |
| 2021-06-30 | $0.00 | $1.00K | $491.41M | (m) | $-385.27M | $106.14M | 3 month · $2.89M | (m) | (m) |
| 2021-03-31 | $0.00 | $1.00K | $392.96M | (m) | $-369.67M | $23.29M | 3 month · $1.61M | (m) | (m) |
| 2020-12-31 | $0.00 | $1.00K | $303.11M | $0.00 | $-376.07M | $-72.96M | 12 month · $10.60M | (m) | (m) |
| 2020-09-30 | $0.00 | $1.00K | $300.47M | $3.00K | $-265.38M | $35.09M | 3 month · $2.97M | (m) | (m) |
| 2020-06-30 | $0.00 | $1.00K | $297.50M | $19.00K | $-253.92M | $43.60M | 3 month · $2.33M | (m) | (m) |
| 2020-03-31 | $0.00 | $1.00K | $295.17M | $225.00K | $-232.79M | $62.61M | 3 month · $2.67M | (m) | (m) |
| 2019-12-31 | $0.00 | $1.00K | $292.51M | $6.00K | $-213.06M | $79.46M | 12 month · $9.62M | (m) | (m) |
| 2019-09-30 | $0.00 | $1.00K | $215.57M | $19.00K | $-198.55M | $17.04M | 3 month · $2.56M | (m) | (m) |
| 2019-06-30 | $0.00 | $1.00K | $212.70M | $43.00K | $-171.57M | $41.18M | 3 month · $2.49M | (m) | (m) |
| 2019-03-31 | $0.00 | $1.00K | $209.37M | $-9.00K | $-134.00M | $75.36M | 3 month · $2.02M | (m) | (m) |
| 2018-12-31 | $0.00 | $1.00K | $207.41M | $0.00 | $-123.03M | $84.38M | 12 month · $6.97M | 12 month · $67.00M | (m) |
| 2018-09-30 | $0.00 | $1.00K | $205.55M | (m) | $-110.58M | $94.97M | 3 month · $1.48M | (m) | (m) |
| 2018-06-30 | $0.00 | $1.00K | $136.69M | (m) | $-98.75M | $37.93M | 3 month · $2.62M | (m) | (m) |
| 2018-03-31 | $0.00 | $1.00K | $134.30M | (m) | $-82.32M | $51.98M | 3 month · $1.01M | 3 month · $67.00M | (m) |
| 2017-12-31 | $0.00 | $0.00 | $0.00 | (m) | $-75.54M | $-75.54M | 12 month · $586.00K | (m) | 12 month · $1.50M |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | $-7.11M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |